Pfizer (NYSE:PFE) Shares Up 1.3%

Pfizer Inc. (NYSE:PFE - Get Free Report)'s share price traded up 1.3% during trading on Monday . The stock traded as high as $25.85 and last traded at $25.72. 7,586,634 shares were traded during trading, a decline of 82% from the average session volume of 41,583,348 shares. The stock had previously closed at $25.40.

Analyst Ratings Changes

A number of analysts have recently weighed in on PFE shares. Argus downgraded shares of Pfizer from a "buy" rating to a "hold" rating in a research report on Friday, March 22nd. Guggenheim initiated coverage on shares of Pfizer in a research note on Friday, February 23rd. They issued a "buy" rating and a $36.00 target price on the stock. TD Cowen downgraded Pfizer from an "outperform" rating to a "market perform" rating and set a $32.00 price target for the company. in a research note on Thursday, January 4th. Finally, Cantor Fitzgerald restated an "overweight" rating and set a $45.00 price objective on shares of Pfizer in a research note on Monday, April 15th. Eleven equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company's stock. According to data from MarketBeat, Pfizer presently has an average rating of "Hold" and a consensus price target of $36.33.

Pfizer Stock Performance

The company has a quick ratio of 0.69, a current ratio of 0.91 and a debt-to-equity ratio of 0.69. The firm has a market capitalization of $145.24 billion, a price-to-earnings ratio of 71.03, a P/E/G ratio of 1.14 and a beta of 0.61. The company has a 50-day moving average price of $26.96 and a 200-day moving average price of $28.36.

Pfizer (NYSE:PFE - Get Free Report) last released its quarterly earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.19) by $0.29. Pfizer had a return on equity of 10.88% and a net margin of 3.62%. The company had revenue of $14.25 billion during the quarter, compared to analysts' expectations of $14.37 billion. During the same quarter in the prior year, the business posted $1.14 earnings per share. The company's revenue for the quarter was down 41.3% compared to the same quarter last year. As a group, equities research analysts forecast that Pfizer Inc. will post 2.24 earnings per share for the current year.

Pfizer Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, June 14th. Shareholders of record on Friday, May 10th will be given a $0.42 dividend. The ex-dividend date of this dividend is Thursday, May 9th. This represents a $1.68 dividend on an annualized basis and a yield of 6.55%. Pfizer's dividend payout ratio (DPR) is 466.67%.

Institutional Trading of Pfizer

Several institutional investors have recently modified their holdings of the company. Trifecta Capital Advisors LLC increased its stake in Pfizer by 3.7% in the 3rd quarter. Trifecta Capital Advisors LLC now owns 9,197 shares of the biopharmaceutical company's stock worth $305,000 after purchasing an additional 325 shares in the last quarter. Confluence Wealth Services Inc. increased its position in shares of Pfizer by 0.5% in the third quarter. Confluence Wealth Services Inc. now owns 65,053 shares of the biopharmaceutical company's stock worth $2,158,000 after acquiring an additional 342 shares in the last quarter. Carr Financial Group Corp raised its holdings in shares of Pfizer by 3.3% during the third quarter. Carr Financial Group Corp now owns 11,012 shares of the biopharmaceutical company's stock valued at $344,000 after acquiring an additional 355 shares during the period. Caldwell Sutter Capital Inc. raised its holdings in shares of Pfizer by 0.5% during the third quarter. Caldwell Sutter Capital Inc. now owns 69,794 shares of the biopharmaceutical company's stock valued at $2,315,000 after acquiring an additional 364 shares during the period. Finally, Advisor OS LLC lifted its position in shares of Pfizer by 1.0% in the 4th quarter. Advisor OS LLC now owns 35,202 shares of the biopharmaceutical company's stock valued at $1,013,000 after acquiring an additional 365 shares in the last quarter. Institutional investors and hedge funds own 68.36% of the company's stock.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.